Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boric acid mouthwash for third molar surgery
NCT04376268Phase 4
Key facts
- Status
- Unknown
- Start
- Jan 2019
- Primary completion
- Nov 2023
- Countries
- 1
- Sponsor
- Van Yuzuncu Yil University
- Modality
- DNA Intercalators/Alkylators
- Drugs
- boric acid
- Conditions
- impacted third molar (I3M)
01
Overview
Phase 4, randomised, triple-blind trial of boric acid in impacted third molar (I3M) (8 arms), sponsored by Van Yuzuncu Yil University. Primary endpoints: Postoperative Pain at 7 days, Postoperative Swelling at 7 days and 1 more. Status: unknown.
02
Design
8 arms- Study design
- RandomizedTriple-blind
Chlorhexidine gluconate
Chlorhexidine + Boric Acid 0.1%
Chlorhexidine + Boric Acid 0.5%
Chlorhexidine + Boric Acid 1%
Chlorhexidine + Boric Acid 1.5%
Chlorhexidine + Boric Acid 2%
2 more in the full profile.
03
Who it enrols
Patients aged 18-40 with impacted mandibular third molar teeth in similar positions, no systemic diseases, no allergies to study drugs, and no recent medication use.
04
Endpoints
Primary
Postoperative Pain
Postoperative Swelling
Postoperative Trismus
Beyond the preview
Go deeper on NCT04376268.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04376268.